COVID-19 vaccine study supports flexible intervals in mixed Pfizer and Oxford/AstraZeneca schedules, NIHR

A standard two-dose Pfizer-BioNTech or Oxford-AstraZeneca vaccine schedule showed a greater antibody increase when given at a 12-week interval, compared to a four-week interval. These are the latest findings from the University of Oxford-led Com-COV study, supported by the National Institute for Health and Care research (NIHR), which has published a paper in the Lancet Respiratory Medicine.
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news